Nanocarriers as an emerging platform for cancer therapy.
Nanotechnology has the potential to revolutionize cancer diagnosis and therapy. Advances in protein engineering and materials science have contributed to novel nanoscale targeting approaches that may bring new hope to cancer patients. Several therapeutic nanocarriers have been approved for clinical use. However, to date, there are only a few clinically approved nanocarriers that incorporate molecules to selectively bind and target cancer cells. This review examines some of the approved formulations and discusses the challenges in translating basic research to the clinic. We detail the arsenal of nanocarriers and molecules available for selective tumour targeting, and emphasize the challenges in cancer treatment.
Peer
Dan
D
Department of Anesthesia, Immune Disease Institute, Harvard Medical School, Boston, Massachusetts 02115, USA.
Karp
Jeffrey M
JM
Hong
Seungpyo
S
Farokhzad
Omid C
OC
Margalit
Rimona
R
Langer
Robert
R
D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000737:chemistry*; D004337:Drug Carriers / Q000737:chemistry*; D004339:Drug Compounding / Q000639:trends*; D050997:Nanomedicine / Q000639:trends*; D049329:Nanostructures / Q000737:chemistry* / Q000648:ultrastructure; D009369:Neoplasms / Q000188:drug therapy*
D000970:Antineoplastic Agents; D004337:Drug Carriers